Need Help?

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening

We report derivation of 30 Patient-Derived Organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical for pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic. The PRMT5 inhibitor EZP015556, shown to target MTAP negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP+ tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004528 HiSeq X Ten 31
EGAD00001004529 HiSeq X Ten 53
EGAD00001005217 NextSeq 500 31
Publications Citations
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.
Proc Natl Acad Sci U S A 116: 2019 26580-26590
218